Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why ...

The pharmaceutical sector has been making headlines for large-scale layoffs, department closures and clinical trial failures.

U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs ...

Clinical trial costs have been rising year-on-year, with companies working to balance the scales and keep studies running despite declining investment. The pharma and biotech sector appeared to be ...

Bachem, a Swiss pharmaceutical ... as they don’t cost as much to develop. This is because brand-name medications are new drugs that require research, development, and clinical trials.

With trial costs rising over the past decade and concerns they’ll keep climbing, companies are seeking ways to manage ...

The price of pharmaceuticals will likely go up soon, and generics are poised to be hit the hardest.

At the same time, drugmakers have come to rely on the U.S. market for the bulk of their revenue. In 2022, the U.S. accounted ...

As a result, there is a need for continued innovation and increased efficiency in terms of drug development to manage cost ... of research and early product development, and the pharma partner ...

The company's expert research team, which has extensive experience and proven results, works flexibly in all phases of pharmaceutical development from the early stage to final drug application.

And while Trump has criticized Ireland for attracting big pharma companies, he’s also suggested he wants to reshore ...